

Date and Time: Friday 12th September 2014 10:00 – 16:30

Minutes: Confirmed

Guideline Development Group MeetingPreterm labour and birthPlace:Royal College of Obstetricians and GynaecologistsLondon

Present:	Jane Norman (JN) (Chair)	(Present for notes 1 – 10)
	Paul Eunson (PE)	(Present for notes 1 – 10)
	Jane Hawdon (JH)	(Present for notes 1 – 10)
	Jane Plumb (JP)	(Present for notes 1 – 10)
	Farrah Pradhan (FP)	(Present for notes 1 – 10)
	Marianne Rowntree (MR)	(Present for notes 1 – 10)
	Meekai To (MT)	(Present for notes 1 – 10)
	Martin Ward-Platt (MWP)	(Present for notes 1 – 10)
	Louise Weaver-Lowe (LW-L)	(Present for notes 1 – 10)

In attendance:

Juliet Kenny (JK) David James (DJ) Paul Jacklin (PJ)	(Present for notes $1 - 10$) (Present for notes $1 - 10$) (Present for notes $1 - 10$)
David James (DJ) Paul Jacklin (PJ)	(Present for notes $1 - 10$)
Paul Jacklin (PJ)	
	(Present for notes 1 – 10)
Hugo Pedder (HP)	(Present for notes 7 – 10)
Grammati Sarri (GS)	(Present for notes 1 – 10)
NICE attendees: Oliver Bailey	(Present for notes 1 – 10)
Other attendees: Sofia Dias (NICE Technical Support Unit (TSU))	(Present for notes 1 – 10)

Observers:

None	

Notes

1. JN welcomed the group to the ninth meeting of this GDG. Apologies were received from Judi Barratt, Shona Burman-Roy and Phillip Owen.

JN asked all the GDG members and other attendees to declare any new interests that they had accrued since GDG 8 and reiterate any interests declared previously that were relevant to the meeting agenda.

MWP

Personal non-pecuniary:

Peer reviewed academic material authored by other GDG members, the material was

Notes

specific to topics in the guideline and related to evidence considered by the GDG.

It was agreed that no interests declared at this meeting or previously warranted exclusion of any GDG members from discussion of evidence or formulation of recommendations at the meeting.

- 2. The minutes of the last meeting were agreed.
- 3. JK introduced the draft review for tocolytic drugs for women in suspected or diagnosed preterm labour (the protocol, the list of excluded studies, the evidence tables, the evidence profiles and evidence summary and the TSU network meta-analysis methods report).
- 4. MG presented an overview of the findings from the network meta-analysis for tocolytic drugs.
- 5. PJ gave a brief presentation reminding the group about the role of health economics in GDG decision making and measures of cost effectiveness in relation to the topic of tocolytic drugs.
- 6. MG presented the results of the draft review for tocolytic drugs. The group had the opportunity to ask questions explanations were provided by the technical team and SD.
- 7. JN led the group through the process of interpreting the evidence and drafting recommendations. Notes were made live on screen.
- 8. PJ gave a presentation updating the group on progress with the health economic analysis being undertaken for the topics of diagnosis and treatment of women in suspected preterm labour (focussing on those aspects relating to tocolytic drug treatment). Example decision-trees was displayed on screen. The GDG had the opportunity to ask questions and provide feedback on baseline probabilities and other aspects of the model design and to ask questions.
- 9. JK presented the draft care pathway (full guideline version). The group had the opportunity to ask questions and provide feedback.
- 10. There was no other business. JN thanked the participants for attending and closed the meeting.

Date, time and venue of the next meeting

Tuesday 4th November 2014, 10:00 – 16:30 at the Royal College of Obstetricians and Gynaecologists, London.